Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2018’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)

- The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlists all their major and minor projects

- The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Ache Laboratorios Farmaceuticos SA

Adamis Pharmaceuticals Corp

Advanced Inhalation Therapies (AIT) Ltd

AlgiPharma AS

Allinaire Therapeutics LLC

Angiocrine Bioscience Inc

apceth Biopharma ...

AB Science SA

Ache Laboratorios Farmaceuticos SA

Adamis Pharmaceuticals Corp

Advanced Inhalation Therapies (AIT) Ltd

AlgiPharma AS

Allinaire Therapeutics LLC

Angiocrine Bioscience Inc

apceth Biopharma GmbH

Aridis Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

AusBio Ltd

Bioneer Corp

BioStem Technologies Inc

Boehringer Ingelheim GmbH

C4X Discovery Holdings PLC

Celon Pharma SA

Chiesi Farmaceutici SpA

China Resources Pharmaceutical Group Ltd

Cipla Ltd

Circassia Pharmaceuticals Plc

CSL Ltd

Cytokinetics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Denovo Biopharma LLC

Diffusion Pharmaceuticals Inc

Domainex Ltd

Enterprise Therapeutics Ltd

Errant Gene Therapeutics LLC

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Grifols SA

Hanmi Pharmaceuticals Co Ltd

iCeutica Inc

Icure Pharmaceutical Inc

InMed Pharmaceuticals Inc

Insmed Inc

Intech Biopharm Ltd

Invion Ltd

Johnson & Johnson

KBP BioSciences Co Ltd

Kissei Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

MedImmune LLC

Mereo Biopharma Group Plc

Meridigen Biotech Co Ltd

Novartis AG

Octapharma AG

OncBioMune Pharmaceuticals Inc

OPKO Health Inc

Orchid Pharma Ltd

Orion Corp

Pfizer Inc

PharmaLundensis AB

Pharmaxis Ltd

Promedior Inc

ProMetic Life Sciences Inc

Pulmatrix Inc

Qu Biologics Inc

Quark Pharmaceuticals Inc

Re-Pharm Ltd

Regeneron Pharmaceuticals Inc

Resolys Bio Inc

Respira Therapeutics Inc

Respiratorius AB

rEVO Biologics Inc

Rhizen Pharmaceuticals SA

SATT North SAS

SolAeroMed Inc

sterna biologicals GmbH & Co KG

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Synairgen Plc

Synovo GmbH

Syntrix Biosystems Inc

Therabron Therapeutics Inc

Theravance Biopharma Inc

Torrent Pharmaceuticals Ltd

Unity Biotechnology Inc

Unizyme Laboratories AS

Verona Pharma Plc

Yungjin Pharm Co Ltd

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Chronic Obstructive Pulmonary Disease (COPD) - Overview 8

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development 9

Chronic ...

Table of Contents

Table of Contents 2

Introduction 7

Chronic Obstructive Pulmonary Disease (COPD) - Overview 8

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development 9

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 29

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 43

Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles 87

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 430

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 450

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 459

Appendix 471

List of Tables

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AusBio Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corp, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by BioStem Technologies Inc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Celon Pharma SA, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by China Resources Pharmaceutical Group Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cipla Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics Inc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Denovo Biopharma LLC, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Enterprise Therapeutics Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics LLC, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Evaxion Biotech ApS, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences Inc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Grifols SA, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica Inc, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports